In vitro studies have shown that physiological doses of genistein (0.5–1.0 μM) upregulate BRCA1 in ER+ human breast cancer cells and in prostate cancer cells (Fan et al, 2006). The gene discussed is BRCA1; the disease is prostate carcinoma.